Background:
MK-4700 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies.
Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.
Since this drug is still in the clinical trial phase, it has the placeholder name MK-4700 rather than a commercial trade name.
The Trial:
This study will investigate safety and effectiveness as an anti-cancer drug of MK-4700, alone, or in combination with Pembrolizumab in patients with advanced malignant kidney cancer.
Kidney cancer participants will be sequentially assigned to one of the below treatment regimes:
- MK-4700 alone
- MK-4700 + Pembrolizumab
Basic Eligibility:
- Clear cell or papillary subtype kidney cancer
- Advanced or metastatic solid tumor
- already tried treatment, but it either stopped working or caused serious side effects
Additional eligibility criteria will apply. Please speak to your doctor.
Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
---|---|---|---|
Hospital / Cancer CentrePrincess Margaret Cancer Centre | Principal InvestigatorNot Given | LocationToronto, ON | Trial StatusRecruiting |
Hospital / Cancer CentreCHU de Québec Université Laval, Hôpital de l'Enfant-Jésus | Principal InvestigatorNot Given | LocationQuebec, QC | Trial StatusRecruiting |